Helix BioPharma (TSE:HBP) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Helix BioPharma Corp. has entered into an asset purchase agreement to acquire an oral immune checkpoint inhibitor from Laevoroc Immunology AG, enhancing its immune-oncology portfolio. This transaction will involve issuing 16.5% of Helix’s shares to acquire intellectual property and assets, pending regulatory approval. The move aims to expand Helix’s pipeline with promising therapeutic candidates for leukemia patients.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
